Active — Not RecruitingPhase 2

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

United States64 participantsStarted 2017-11-03

Plain-language summary

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: • Ruxolitinib

Who can participate

Age range60 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓--Or participants have pathologically confirmed MDS as defined by:

What they're measuring

1-year GVHD/relapse free survival rate (GRFS rate)

Timeframe: 1 Year

Trial details

NCT IDNCT03286530

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Acute Myeloid Leukemia trials